156 related articles for article (PubMed ID: 25345821)
1. Tyrosine kinase inhibitors in the treatment of prostate cancer: taking the next step in clinical development.
Ojemuyiwa MA; Madan RA; Dahut WL
Expert Opin Emerg Drugs; 2014 Dec; 19(4):459-70. PubMed ID: 25345821
[TBL] [Abstract][Full Text] [Related]
2. Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer.
Edwards J
Expert Opin Investig Drugs; 2010 May; 19(5):605-14. PubMed ID: 20367532
[TBL] [Abstract][Full Text] [Related]
3. Emerging tyrosine kinase inhibitors for esophageal cancer.
Ku GY; Ilson DH
Expert Opin Emerg Drugs; 2013 Jun; 18(2):219-30. PubMed ID: 23725567
[TBL] [Abstract][Full Text] [Related]
4. Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer.
Gallick GE; Corn PG; Zurita AJ; Lin SH
Future Med Chem; 2012 Jan; 4(1):107-19. PubMed ID: 22168167
[TBL] [Abstract][Full Text] [Related]
5. Cancer multitarget pharmacology in prostate tumors: tyrosine kinase inhibitors and beyond.
Bologna M; Vicentini C; Muzi P; Pace G; Angelucci A
Curr Med Chem; 2011; 18(19):2827-35. PubMed ID: 21651496
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
Montero JC; Seoane S; Ocaña A; Pandiella A
Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
[TBL] [Abstract][Full Text] [Related]
7. Bone targeted therapies in metastatic castration-resistant prostate cancer.
Rajpar S; Fizazi K
Cancer J; 2013; 19(1):66-70. PubMed ID: 23337759
[TBL] [Abstract][Full Text] [Related]
8. Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer.
Lee CC; Shiao HY; Wang WC; Hsieh HP
Expert Opin Investig Drugs; 2014 Oct; 23(10):1333-48. PubMed ID: 24921970
[TBL] [Abstract][Full Text] [Related]
9. Src as a therapeutic target in men with prostate cancer and bone metastases.
Saad F
BJU Int; 2009 Feb; 103(4):434-40. PubMed ID: 19154462
[TBL] [Abstract][Full Text] [Related]
10. From bevacizumab to tasquinimod: angiogenesis as a therapeutic target in prostate cancer.
Schweizer MT; Carducci MA
Cancer J; 2013; 19(1):99-106. PubMed ID: 23337763
[TBL] [Abstract][Full Text] [Related]
11. Linking γ-aminobutyric acid A receptor to epidermal growth factor receptor pathways activation in human prostate cancer.
Wu W; Yang Q; Fung KM; Humphreys MR; Brame LS; Cao A; Fang YT; Shih PT; Kropp BP; Lin HK
Mol Cell Endocrinol; 2014 Mar; 383(1-2):69-79. PubMed ID: 24296312
[TBL] [Abstract][Full Text] [Related]
12. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.
Ozkan EE
Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884
[TBL] [Abstract][Full Text] [Related]
13. SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer.
Saad F; Lipton A
Cancer Treat Rev; 2010 Apr; 36(2):177-84. PubMed ID: 20015594
[TBL] [Abstract][Full Text] [Related]
14. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.
Gridelli C; de Marinis F; Cappuzzo F; Di Maio M; Hirsch FR; Mok T; Morgillo F; Rosell R; Spigel DR; Yang JC; Ciardiello F
Clin Lung Cancer; 2014 May; 15(3):173-81. PubMed ID: 24486058
[TBL] [Abstract][Full Text] [Related]
15. Novel dual Src/Abl inhibitors for hematologic and solid malignancies.
Schenone S; Brullo C; Musumeci F; Botta M
Expert Opin Investig Drugs; 2010 Aug; 19(8):931-45. PubMed ID: 20557276
[TBL] [Abstract][Full Text] [Related]
16. Novel approaches to the development of tyrosine kinase inhibitors and their role in the fight against cancer.
Zámečníkova A
Expert Opin Drug Discov; 2014 Jan; 9(1):77-92. PubMed ID: 24294890
[TBL] [Abstract][Full Text] [Related]
17. Role of tyrosine kinase inhibitors in the treatment of advanced colorectal cancer.
Grávalos C; Cassinello J; Fernández-Rañada I; Holgado E
Clin Colorectal Cancer; 2007 Nov; 6(10):691-9. PubMed ID: 18039422
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine kinase inhibitors (TKIs) in human and pet tumours with special reference to breast cancer: a comparative review.
Ranieri G; Pantaleo M; Piccinno M; Roncetti M; Mutinati M; Marech I; Patruno R; Rizzo A; Sciorsci RL
Crit Rev Oncol Hematol; 2013 Nov; 88(2):293-308. PubMed ID: 23768779
[TBL] [Abstract][Full Text] [Related]
19. Emerging tyrosine kinase inhibitors for the treatment of hepatocellular carcinoma.
de Rosamel L; Blanc JF
Expert Opin Emerg Drugs; 2017 Jun; 22(2):175-190. PubMed ID: 28604110
[TBL] [Abstract][Full Text] [Related]
20. Dacomitinib, a new therapy for the treatment of non-small cell lung cancer.
Brzezniak C; Carter CA; Giaccone G
Expert Opin Pharmacother; 2013 Feb; 14(2):247-53. PubMed ID: 23294134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
